Palisade Bio reports early PALI-2108 activity in ulcerative colitis and Crohn’s disease
+1 new source since this summary was written
Palisade Bio reported five poster presentations on PALI-2108 at the ACG 2026 meeting in Nashville. In a seven-day ulcerative-colitis study, all five participants responded clinically and two achieved remission, while a separate 14-day Crohn’s disease study showed a 47.5% mean decline in an endoscopic disease score. Two presentations received ACG Presidential Poster Awards, and the drug remains investigational.
Why it matters
The findings support Palisade Bio’s ongoing Phase 2 development of PALI-2108. The company noted that the studies were small, brief, open-label and without placebo controls, so larger studies are needed to confirm the results.
Key facts
- 1Palisade Bio presented findings from five posters at the ACG 2026 Annual Scientific Meeting, with two receiving ACG Presidential Poster Awards. investing.com
- 2In a seven-day ulcerative colitis study of five patients, all achieved clinical response and two achieved clinical remission. investing.com
- 3The ulcerative colitis study recorded a 62.8% mean reduction in modified Mayo score. investing.com
- 4In a separate 14-day study of five adults with symptomatic ileal fibrostenotic Crohn’s disease, the mean reduction in the Simple Endoscopic Score for Crohn’s Disease was 47.5%; two patients achieved endoscopic response and two achieved endoscopic remission. investing.com
- 5Palisade Bio is evaluating once-daily PALI-2108 at 15 mg and 30 mg against placebo in a Phase 2 ulcerative colitis study involving approximately 204 patients. investing.com
- 6PALI-2108 has not been approved for any indication. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.